Last kr3.98 DKK
Change Today 0.00 / 0.00%
Volume 0.0
As of 11:35 AM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

topotarget a/s (TOPO) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TOPOTARGET A/S (TOPO)

Related News

No related news articles were found.

topotarget a/s (TOPO) Related Businessweek News

No Related Businessweek News Found

topotarget a/s (TOPO) Details

Topotarget A/S develops and commercializes a portfolio of oncology product candidates. Its lead compound includes Belinostat (PXD101), a novel HDAC inhibitor in late-stage clinical development for the treatment of hematological malignancies and solid tumors. The company has operations in Denmark, Europe, and the United States. It has a collaboration agreement primarily with Spectrum Pharmaceuticals Inc. Topotarget A/S was founded in 2000 and is headquartered in Copenhagen, Denmark. As of July 22, 2014, Topotarget A/S operates as a subsidiary of BioAlliance Pharma.

12 Employees
Last Reported Date: 05/8/14
Founded in 2000

topotarget a/s (TOPO) Top Compensated Officers

Executive Chairman, Chairman of Audit Committ...
Total Annual Compensation: --
Total Annual Compensation: --
Director of Global Regulatory Affairs
Total Annual Compensation: --
Director of Finance
Total Annual Compensation: --
Director of Science
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

topotarget a/s (TOPO) Key Developments

Topotarget A/S(CPSE:TOPO) dropped from OMX Nordic All-Share Index

Topotarget A/S will be removed from the OMX Nordic All-Share Index.

Topotarget A/S(CPSE:TOPO) dropped from OMX Nordic Small Cap Index

Topotarget A/S will be removed from the OMX Nordic Small Cap Index.

Anders Vadsholt to Resign as CEO of Topotarget

Topotarget announced that Anders Vadsholt will resign his position as CEO of Topotarget. Anders has been CEO since August 30, 2012 and will continue in his present position until July 31, 2014 or at the latest until the expected approval of the merger. The CEO of BioAlliance Pharma, Judith Greciet, will take over the position as CEO of the combined company, OnXeo, when the merger is approved.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TOPO:DC kr3.98 DKK 0.00

TOPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TOPO.
View Industry Companies

Industry Analysis


Industry Average

Valuation TOPO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TOPOTARGET A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at